Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin plus 7+3 for newly diagnosed AML and idasanutlin maintenance
CTR20200274Phase 2Terminated
- Sponsor
- Roche
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idasanutlin in acute myeloid leukemia (AML), sponsored by Roche. Started Mar 2020; status: terminated.
02
Drugs
idasanutlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20200274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200274.